| A comparison of automatic differentiation and continuous sensitivity analysis for derivatives of differential equation solutions Y Ma, V Dixit, MJ Innes, X Guo, C Rackauckas 2021 IEEE High Performance Extreme Computing Conference (HPEC), 1-9, 2021 | 158 | 2021 |
| PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool J Nyberg, S Ueckert, EA Strömberg, S Hennig, MO Karlsson, AC Hooker Computer methods and programs in biomedicine 108 (2), 789-805, 2012 | 119 | 2012 |
| The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models J Ribbing, J Nyberg, O Caster, EN Jonsson Journal of pharmacokinetics and pharmacodynamics 34, 485-517, 2007 | 107 | 2007 |
| Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies J Nyberg, C Bazzoli, K Ogungbenro, A Aliev, S Leonov, S Duffull, ... British journal of clinical pharmacology 79 (1), 6-17, 2015 | 97 | 2015 |
| Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models C Vong, M Bergstrand, J Nyberg, MO Karlsson The AAPS journal 14, 176-186, 2012 | 73 | 2012 |
| Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients IK Delattre, FT Musuamba, J Nyberg, FS Taccone, PF Laterre, ... Therapeutic drug monitoring 32 (6), 749-756, 2010 | 72 | 2010 |
| Simultaneous optimal experimental design on dose and sample times J Nyberg, MO Karlsson, AC Hooker Journal of pharmacokinetics and pharmacodynamics 36, 125-145, 2009 | 52 | 2009 |
| Accelerated predictive healthcare analytics with pumas, a high performance pharmaceutical modeling and simulation platform C Rackauckas, Y Ma, A Noack, V Dixit, PK Mogensen, S Byrne, ... BioRxiv, 2020.11. 28.402297, 2020 | 47 | 2020 |
| Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin L Keutzer, H You, A Farnoud, J Nyberg, SG Wicha, G Maher-Edwards, ... Pharmaceutics 14 (8), 1530, 2022 | 46 | 2022 |
| High-spin states in 183Pt J Nyberg, A Johnson, MP Carpenter, CR Bingham, LH Courtney, ... Nuclear Physics A 511 (1), 92-116, 1990 | 45 | 1990 |
| Adaptive‐optimal design in PET occupancy studies S Zamuner, VL Di Iorio, J Nyberg, RN Gunn, VJ Cunningham, R Gomeni, ... Clinical Pharmacology & Therapeutics 87 (5), 563-571, 2010 | 37 | 2010 |
| Population pharmacokinetics of edoxaban in patients with symptomatic deep‐vein thrombosis and/or pulmonary embolism—the Hokusai‐VTE phase 3 study R Niebecker, S Jönsson, MO Karlsson, R Miller, J Nyberg, EHJ Krekels, ... British Journal of Clinical Pharmacology 80 (6), 1374-1387, 2015 | 32 | 2015 |
| Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design HE Silber, J Nyberg, AC Hooker, MO Karlsson Journal of pharmacokinetics and pharmacodynamics 36, 281-295, 2009 | 28 | 2009 |
| A pharmacokinetic-pharmacodynamic model of morphine exposure and subsequent morphine consumption in postoperative pain RV Juul, J Nyberg, TM Lund, S Rasmussen, M Kreilgaard, LL Christrup, ... Pharmaceutical research 33, 1093-1103, 2016 | 27 | 2016 |
| Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin S Hennig, J Nyberg, S Fanta, JT Backman, K Hoppu, AC Hooker, ... The Journal of Clinical Pharmacology 52 (3), 347-360, 2012 | 27 | 2012 |
| Serial correlation in optimal design for nonlinear mixed effects models J Nyberg, R Höglund, M Bergstrand, MO Karlsson, AC Hooker Journal of pharmacokinetics and pharmacodynamics 39, 239-249, 2012 | 18 | 2012 |
| Edoxaban Exposure‐Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep‐Vein Thrombosis or Pulmonary Embolism J Nyberg, KE Karlsson, S Jönsson, OQP Yin, R Miller, MO Karlsson, ... CPT: Pharmacometrics & Systems Pharmacology 5 (4), 222-232, 2016 | 17 | 2016 |
| Population optimal experimental design for discrete type data J Nyberg, MO Karlsson, AC Hooker PAGE (Population Approach Group Europe) 18, Abstr 1468, 2009 | 15 | 2009 |
| An introduction to the full random effects model G Yngman, H Bjugård Nyberg, J Nyberg, EN Jonsson, MO Karlsson CPT: pharmacometrics & systems pharmacology 11 (2), 149-160, 2022 | 12 | 2022 |
| Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment E Sjögren, J Nyberg, MO Magnusson, H Lennernäs, A Hooker, ... Drug Metabolism and Disposition 39 (5), 858-863, 2011 | 12 | 2011 |
